These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36471683)

  • 1. Remarkable Intracranial Response to Sotorasib in a Patient With
    Yeh J; Marks JA; Alzeer AH; Sloan EA; Varghese R; Paudel N; Reuss JE; Bergquist PJ; Liu SV; Kim C
    JTO Clin Res Rep; 2022 Dec; 3(12):100428. PubMed ID: 36471683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotorasib Shows Intracranial Activity in Patients with
    Koster KL; Appenzeller C; Lauber A; Früh M; Schmid S
    Case Rep Oncol; 2022; 15(2):720-725. PubMed ID: 36157699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
    Iska S; Alley EW
    Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of sotorasib against brain metastases from NSCLC harboring
    Inno A; Marchetti F; Valerio M; Giaj Levra N; Alongi F; Foti G; Gori S
    Drug Target Insights; 2023; 17():90-91. PubMed ID: 37408855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.
    Yang J; Huang J; Yuan G; Lin XC; Chen HJ; Yang JJ
    Clin Case Rep; 2024 Jun; 12(6):e8866. PubMed ID: 38799516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report.
    Jia X; Liu M; Cheng Z
    AME Case Rep; 2024; 8():48. PubMed ID: 38711902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
    Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
    JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
    Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CodeBreak 200: Sotorasib Has Not Broken the KRAS
    Zhang SS; Lee A; Nagasaka M
    Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.
    Wang MX; Zhu P; Shi Y; Sun QM; Dong WH
    World J Clin Cases; 2024 Sep; 12(25):5805-5813. PubMed ID: 39247747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with
    Zhou KI; Lin C; Tseng CL; Ramnath N; Dowell JE; Kelley MJ
    JTO Clin Res Rep; 2024 May; 5(5):100670. PubMed ID: 38746048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
    Brazel D; Kim J; Ou SI
    Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.